@erman_akkus : 💊Cancer drug approval with immature OS data @TheLancetOncol 🚨Among studies with OS as an endpoint (n=95), 41% (n=39) had immature OS data when approved 🚨Of those, only 32% (n=12) showed OS benefit when the data became mature ⁉️Balance between ensuring patients with unmet • TwiCopy

Erman Akkus

@erman_akkus

+ Follow

MD, medical #oncology, internal #medicine specialist, @AnkaraUni, Sharing&discussing #cancer science 🧬

ID: 247382528

calendar_today04-02-2011 17:44:35

1,1K Tweet

2,2K Followers

854 Following

Erman Akkus

@erman_akkus

4 months ago

💊Cancer drug approval with immature OS data The Lancet Oncology 🚨Among studies with OS as an endpoint (n=95), 41% (n=39) had immature OS data when approved 🚨Of those, only 32% (n=12) showed OS benefit when the data became mature ⁉️Balance between ensuring patients with unmet

💊Cancer drug approval with immature OS data
<a href="/TheLancetOncol/">The Lancet Oncology</a>

🚨Among studies with OS as an endpoint (n=95), 41% (n=39) had immature OS data when approved

🚨Of those, only 32% (n=12) showed OS benefit when the data became mature

⁉️Balance between ensuring patients with unmet